<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=utf-8"><meta name=Generator content="Microsoft Word 15 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
        {font-family:"Cambria Math";
        panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
        {font-family:Calibri;
        panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
        {font-family:"Helvetica Neue";}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
        {margin:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
        {mso-style-priority:99;
        color:blue;
        text-decoration:underline;}
p.gmail-p1, li.gmail-p1, div.gmail-p1
        {mso-style-name:gmail-p1;
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman",serif;}
p.gmail-p2, li.gmail-p2, div.gmail-p2
        {mso-style-name:gmail-p2;
        mso-margin-top-alt:auto;
        margin-right:0cm;
        mso-margin-bottom-alt:auto;
        margin-left:0cm;
        font-size:12.0pt;
        font-family:"Times New Roman",serif;}
span.gmail-s1
        {mso-style-name:gmail-s1;}
span.EmailStyle23
        {mso-style-type:personal-reply;
        font-family:"Calibri",sans-serif;
        color:windowtext;}
.MsoChpDefault
        {mso-style-type:export-only;
        font-size:10.0pt;}
@page WordSection1
        {size:612.0pt 792.0pt;
        margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
        {page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple style='word-wrap:break-word'><div class=WordSection1><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'> See below for info on a presentation on Active Surveillance.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Zoom link provided.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Take care & stay well.<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'><o:p> </o:p></span></p><p class=MsoNormal><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;mso-fareast-language:EN-US'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal><b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'>From:</span></b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'> walter.eadie@cogeco.ca <br><b>Sent:</b> February 12, 2021 3:05 PM<br><b>To:</b> PC Support Groups <walter.eadie@cogeco.ca><br><b>Subject:</b> FW: Presentation on Active Surveillance FEB 27th<o:p></o:p></span></p></div></div><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'>From Phil Segal, who will be one of the moderators on this Webinar<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'><o:p> </o:p></span></p><div><div style='border:none;border-top:solid #E1E1E1 1.0pt;padding:3.0pt 0cm 0cm 0cm'><p class=MsoNormal style='margin-bottom:12.0pt'><b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'>From:</span></b><span lang=EN-US style='font-size:11.0pt;font-family:"Calibri",sans-serif'> Philip Segal <<a href="mailto:segalfamily@sympatico.ca">segalfamily@sympatico.ca</a>> <br><b>Sent:</b> Friday, February 12, 2021 2:48 PM</span><span style='font-size:11.0pt;font-family:"Calibri",sans-serif;color:#1F497D'><o:p></o:p></span></p></div></div><div><div><p class=MsoNormal>Hi everyone.<o:p></o:p></p></div><div><p class=MsoNormal>Active Surveillance Patients International <span style='color:#1F497D'>(ASPI) </span>will be hearing its first speaker at <b><u><span style='font-size:18.0pt'>11 am Eastern on Feb. 27</span></u></b>. Dr. Chris Bangma, the father of AS in Europe, will share a different view on AS. Hope you can join us. Here's the details:<o:p></o:p></p></div><div><p class=MsoNormal><o:p> </o:p></p></div><div><p class=gmail-p1 style='margin:0cm;font-variant-numeric:normal;font-variant-east-asian:normal;font-stretch:normal'><b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'>Dr. Chris Bangma, Chairman of Urology at Erasmus University and Academic Hospital in Rotterdam, The Netherlands, will be the inaugural speaker for Active Surveillance Patients International session at 11 a.m. Eastern U.S. on <u><span style='background:yellow;mso-highlight:yellow'>Saturday, February 27, 2021</span></u>. Dr. Bangma’s topic will be <span class=gmail-s1>“The Past Present and Future of Active Surveillance:  A European View.”</span></span></b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'><o:p></o:p></span></p><p class=gmail-p1 style='margin:0cm;font-variant-numeric:normal;font-variant-east-asian:normal;font-stretch:normal'><b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'>Among other areas, he will cover the role of PSA testing in Europe, the role of biopsies and mpMRI scanning, genomics, how AS was developed in Europe, how AS works within the Dutch healthcare system, and what the future holds in terms of liquid biopsy and artificial intelligence.</span></b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'><o:p></o:p></span></p><p class=gmail-p1 style='margin:0cm;font-variant-numeric:normal;font-variant-east-asian:normal;font-stretch:normal'><b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'>To register:</span></b><span style='font-size:14.0pt;font-family:"Helvetica Neue"'><o:p></o:p></span></p><p class=gmail-p2 style='margin:0cm;font-variant-numeric:normal;font-variant-east-asian:normal;font-stretch:normal'><span class=gmail-s1><span style='font-family:"Helvetica Neue";color:#DCA10D'><a href="https://us02web.zoom.us/meeting/register/tZ0sdOGuqzsiHdGpxh8UtE-ygivEn8loBvTS">https://us02web.zoom.us/meeting/register/tZ0sdOGuqzsiHdGpxh8UtE-ygivEn8loBvTS</a></span></span><span style='font-family:"Helvetica Neue";color:#DCA10D'><o:p></o:p></span></p></div></div></div></body></html>